We report the results of a multidisciplinary seminar approaching the recognition and construction of hepatitis C as a health issue in Mexico. Its prevalence is 1.4% and its incidence is estimated in 19 300 new cases per year.As transfusion decreases as a risk factor, the relevance of nosocomial transmission and use of intravenous or intranasal drugs increases. It is necessary to develop new contents for the social representation and risk perception of the disease. Response guided treatment based on PCR-RNA has modified the treatment schemes, a very important issue when considering policies for management. Legislation about hepatitis C in the country is limited. Assignments of the Federal Government and the federative entities in the country regarding health issues are framed in the 13th article of the General Mexican health law. It is necessary to advance towards the development of a public health policy at the national level for hepatitis C.